---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-000209"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2026-01-02T23:59:59+00:00"
generated_at: "2026-05-16T11:50:20.164147+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zura Bio terminates prior Stone Peach/BAFFX17 agreements, issues 8.66M shares to Athanor Capital

## Summary
- Terminated Letter Agreements with Stone Peach and BAFFX17; entered new Athanor Agreement on Dec 29, 2025.
- Issued 8,657,402 Class A ordinary shares to Athanor; $7.325M upfront fee and $25M milestone payment on change of control or first regulatory approval.
- Athanor receives piggyback registration rights and 2% net sales royalty on tibulizumab (ZB-106) from the Lilly license.
- Audit Subcommittee review completed; no financial statement impact or employee misconduct found.
- New terms deemed more commercially advantageous; prior agreements voided with broad releases.

## SEC filing metadata
- accession: 0001104659-26-000209
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2026-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465926000209/0001104659-26-000209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465926000209/tm2531128d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-000209
- JSON: https://secwatch.observer/filing/0001104659-26-000209.json
- Plain text: https://secwatch.observer/filing/0001104659-26-000209.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.